Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
United Therapeutics Corporation

United Therapeutics Corporation (UTHR) Stock Overview

Explore United Therapeutics Corporation’s financial performance, market position, analyst ratings, and future outlook.

UTHR●NASDAQ
HealthcareBiotechnology
$541.70
$29.68(5.19%)
U.S. Market opens in 0h 24m

United Therapeutics Corporation (UTHR)

Meyka AI Score

Z

Key Financials

Market Cap23B
P/E Ratio18.02
EPS (TTM)$27.95
ROE0.20%
Fundamental Analysis

AI Price Forecasts

1 Month$499.07
3 Months$698.87
1 Year Target$515.56

UTHR Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of United Therapeutics Corporation (NASDAQ: UTHR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, United Therapeutics Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of UTHR on the NASDAQ shows an RSI of 60.05, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $515.56 for the NASDAQ listing.

Key metrics behind United Therapeutics Corporation's NASDAQ-traded stock include a P/E ratio of 18.02 and a market capitalization of 23B. Combined with our AI analysis, these give both institutional and retail investors a clear view of UTHR on the NASDAQ.

Price Performance (NASDAQ: UTHR)

1-Day Change
-5.19%
5-Day Change
14.27%
1-Month Change
10.10%
3-Month Change
-2.56%
6-Month Change
-4.09%
Year-to-Date (YTD) Change
11.17%
1-Year Change
22.16%
3-Year Change
143.86%
5-Year Change
192.23%
All-Time (Max) Change
8789.44%

Contact Information

https://www.unither.com
301 608 9292
1040 Spring Street, Silver Spring, MD, 20910

Company Facts

14,000 Employees
IPO DateJun 17, 1999
CountryUS
Actively Trading

Frequently Asked Questions